Please login to the form below

Not currently logged in
Email:
Password:

Astellas makes offer to buy OSI

Global pharma company, Astellas, is to commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals

Global pharmaceutical company, Astellas, is to commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals – a biotechnology company focussed on the discovery, development and commercialisation of molecular targeted therapies in oncology, diabetes and obesity. The acquisition would support Astellas' growth strategy of becoming a leader in oncology, providing the company with a top-tier oncology business in the US and an expanded product portfolio and pipeline.

Astellas' offer is for $52 per share in cash, which represents a 40 per cent premium to the biotechnology company's closing price on February 26, or an aggregate of approximately $3.5bn on a fully diluted basis. The offer is not subject to any financial considerations.

Astellas said that despite letters reiterating Astellas' interest in March and June 2009 and several face-to-face meetings, including a meeting between the two CEOs on February 12, 2010, OSI had refused to engage in a meaningful discussion. As a result Astellas had opted to go directly to OSI stakeholders. 

Following successful completion of the tender offer, a merger will be concluded.

Masafumi Nogimori, president and CEO of Astellas, commented: "This offer follows our attempts over the past 13 months to engage OSI in meaningful discussions. We firmly believe in the compelling strategic rationale behind the combination and the opportunity it provides to the OSI stockholder to realise full and fair value, in cash, immediately."

1st March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics